



GLOBAL JOURNAL OF MEDICAL RESEARCH: K
INTERDISCIPLINARY

Volume 14 Issue 3 Version 1.0 Year 2014

Type: Double Blind Peer Reviewed International Research Journal

Publisher: Global Journals Inc. (USA)

Online ISSN: 2249-4618 & Print ISSN: 0975-5888

Potential Health Benefits and Adverse Effects Associated with Phytate in Foods: A Review

By Habtamu Fekadu Gemedo

Addis Ababa University, Ethiopia

Abstract- Phytate (myo-inositol (1,2,3,4,5,6) hexakis - phosphate), a naturally compound formed during maturation of plant seeds and grains is a common constituent of plant-derived foods. This paper is aimed to review the scientific information concerning the potential health benefits and adverse effects associated with phytate in foods. The adverse health effects of phytate in the diet is its effect on mineral uptake. Minerals of concern in this regard would include Zn^{2+} , $Fe^{2+/3+}$, Ca^{2+} , Mg^{2+} , Mn^{2+} , and Cu^{2+} . Especially zinc and iron deficiencies were reported as a consequence of high phytate intakes. In addition, a the adverse effect on the nutritional value of protein by dietary phytate is discussed. Consumption of phytate, however, seems not to have only adverse health effects but also potential benefits on human health. Dietary phytate was reported to prevent kidney stone formation, protect against diabetes mellitus, caries, atherosclerosis and coronary heart disease as well as against a variety of cancers.

Keywords: *antinutrient, phytate, health benefits, health effects, human nutrition.*

GJMR-K Classification: *NLMC Code: QU 50*



Strictly as per the compliance and regulations of:



© 2014. Habtamu Fekadu Gemedo. This is a research/review paper, distributed under the terms of the Creative Commons Attribution-Noncommercial 3.0 Unported License <http://creativecommons.org/licenses/by-nc/3.0/>), permitting all non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Potential Health Benefits and Adverse Effects Associated with Phytate in Foods: A Review

Habtamu Fekadu Gemedu

Abstract- Phytate (myo-inositol (1,2,3,4,5,6) hexakis - phosphate), a naturally compound formed during maturation of plant seeds and grains is a common constituent of plant-derived foods. This paper is aimed to review the scientific information concerning the potential health benefits and adverse effects associated with phytate in foods. The adverse health effects of phytate in the diet is its effect on mineral uptake. Minerals of concern in this regard would include Zn²⁺, Fe^{2+/3+}, Ca²⁺, Mg²⁺, Mn²⁺, and Cu²⁺. Especially zinc and iron deficiencies were reported as a consequence of high phytate intakes. In addition, a the adverse effect on the nutritional value of protein by dietary phytate is discussed. Consumption of phytate, however, seems not to have only adverse health effects but also potential benefits on human health. Dietary phytate was reported to prevent kidney stone formation, protect against diabetes mellitus, caries, atherosclerosis and coronary heart disease as well as against a variety of cancers.

Keywords : antinutrient, phytate, health benefits, health effects, human nutrition.

I. INTRODUCTION

Phytate (is also known as Inositol hexakis - phosphate (InsP₆)) is the salt form of phytic acid, are found in plants, animals and soil. It is primarily present as a salt of the mono- and divalent cations K⁺, Mg²⁺, and Ca²⁺ and accumulates in the seeds during the ripening period. Phytate is regarded as the primary storage form of both phosphate and inositol in plant seeds and grains [1]. In addition, phytate has been suggested to serve as a store of cations, of high energy phosphoryl groups, and, by chelating free iron, as a potent natural anti-oxidant [2,3].

Phytate is ubiquitous among plant seeds and grains, comprising 0.5 to 5 percent (w/w) [1]. The phosphorus bound to phytate is not typically bio-available to any animal that is non-ruminant. Ruminant animals, such as cows and sheep, chew, swallow, and then regurgitate their food. This regurgitated food is known as cud and is chewed a second time. Due to an enzyme located in their first stomach chamber, the rumen, these animals are able to separate, and process the phosphorus in phytates. Humans and other non-ruminant animals are unable to do so [4].

Phytate works in a broad pH-region as a highly negatively charged ion, and therefore its presence in the diet has a negative impact on the bioavailability of divalent, and trivalent mineral ions such as Zn²⁺, Fe^{2+/3+}, Ca²⁺, Mg²⁺, Mn²⁺, and Cu²⁺ [6]. Whether or not high levels of consumption of phytate-containing foods will result in mineral deficiency will depend on what else is being consumed. In areas of the world where cereal proteins are a major and predominant dietary factor, the associated phytate intake is a cause for concern [27].

Besides, phytate has also been reported to form complexes with proteins at both low, and high pH values. These complex formations alter the protein structure, which may result in decreased protein solubility, enzymatic activity, and proteolytic digestibility. The phytate degrading enzyme, phytase, is in vogue for degrading phytate during food processing, and in the gastrointestinal tract. The major concern about the presence of phytate in the diet is its negative effect on mineral uptake [28]. Phytate markedly decrease Ca bioavailability, and the Ca:Phy molar ratio has been proposed as an indicator of Ca bioavailability. The critical molar ratio of Ca: Phy is reported to be 6:1 [29]. In human studies, Phy:Zn molar ratios of 15:1 have been associated with reduced zinc bioavailability, and the molar ratio [Ca][Phy]/[Zn] is a better predictor of zinc availability, because calcium exacerbates phytate's effect on zinc absorption, and if the values were greater than 0.5 mol/kg, there would be interference with the availability of zinc [30].




Figure 1 : Structure of Phytate (InsP₆), empirical formula = C₆P₆O₂₄H₁₈

Author : Center for Food Science and Nutrition, Addis Ababa University, Addis Ababa, Ethiopia. Food Technology and Process Engineering Department, Wollega University, Nekemte, Ethiopia. e-mails: fekadu_habtamu@yahoo.com, simbokom@gmail.com

At the same time, phytate may have beneficial roles as an Antioxidant, and Anticarcinogen [31]. The outcome of surveillance of populations consuming vegetarian-type diets has shown lower incidence of Cancer, which suggests that phytate has an Anticarcinogen effect [32]. Dietary phytate may have health benefits for Diabetes patients because it lowers the blood glucose response by reducing the rate of starch digestion and slowing gastric emptying. Likewise, phytate has also been shown to regulate Insulin secretion [33]. It is believed that phytate reduces Blood clots, Cholesterol, and Triglycerides, and thus prevents Heart diseases. It is also suggested that it prevents renal stone development. It is used as a complexing agent for removal of traces of heavy metal ions [34].

Depending on the amount of plant-derived foods in the diet, and the grade of food processing, the daily intake of phytate can be as high as 4500 mg. On average, daily intake of phytate was estimated to be 2000–2600 mg for vegetarian diets as well as diets of inhabitants of rural areas in developing countries, and 150–1400 mg for mixed diets [35, 37, 38]. Among the cooking treatments boiling appeared effective to reduce the phytate level, which could reduce as high as 20% of phytate [36, 39]. However, the updated information on health benefits and adverse effects of phytate in foods is scant. Therefore, the objective of this review is to assess updated scientific information of the potential health benefits and adverse effects associated with phytate in foods.

II. ADVERSE HEALTH EFFECTS OF PHYTATE

The major concern about the presence of phytate in the diet is its negative effect on mineral uptake. Minerals of concern in this regard would include Zn^{2+} , $Fe^{2+}/3^{+}$, Ca^{2+} , Mg^{2+} , Mn^{2+} , and Cu^{2+} [13,14], but also a negative effect on the nutritional value of protein [5,7].

a) Effect on mineral uptake

Phytate forms complexes with numerous divalent and trivalent metal cations. Stability and solubility of the metal cation-phytate complexes depends on the individual cation, the pH-value, the phytate:cation molar ratio, and the presence of other compounds in the solution [15]. Phytate has six reactive phosphate groups and meets the criterion of a chelating agent. In fact, a cation can bind to one or more phosphate group of a single phytate molecule or bridge two or more phytate molecules [3, 40]. Most phytates tend to be more soluble at lower compared to higher pH-values [16]. Solubility of phytates increase at pH-values lower than 5.5-6.0 with Ca^{2+} , 7.2-8.0 with Mg^{2+} and 4.3-4.5 with Zn^{2+} as the counter ion. In contrast, ferric phytate is insoluble at pH values in the range of 1.0 to 3.5 at equimolar Fe^{3+} : phytate ratios and solubility increases above pH 4 [17]. Another important fact is the

synergistic effect of secondary cations, among which Ca^{2+} has been most prominently mentioned [18, 41]. Two cations may, when present simultaneously, act jointly to increase the quantity of phytate precipitation. For example, Ca^{2+} enhanced the incorporation or adsorption of Zn^{2+} into phytate by formation of a calcium-zinc phytate. The effect of Ca^{2+} on the amount of Zn^{2+} co-precipitating with phytate is dependent on the Zn^{2+} : phytate molar ratio. For high Zn^{2+} : phytate molar ratios, Ca^{2+} displaces Zn^{2+} from phytate binding sites and increases its solubility. The amount of free Zn^{2+} is directly proportional to the Ca^{2+} -concentration. For low Zn^{2+} : phytate molar ratios, Ca^{2+} potentiates the precipitation of Zn^{2+} as phytate. Thus, higher levels of Ca^{2+} result in a more extensive precipitation of the mixed phytates. Mg^{2+} also has been shown in vitro to potentiate the precipitation of Zn^{2+} in the presence of phytate, however, Mg^{2+} has been found to exert a less pronounced effect on Zn^{2+} -solubility than Ca^{2+} [18, 42].

The knowledge about the interaction of partially phosphorylated myo-inositol phosphates with different cations is limited. Recent studies have shown that myo-inositol pentakis-, tetrakis- and trisphosphates have a lower capacity to bind cations at pH-values ranging from 5.0 to 7.0 [19]. The capacity to bind cations was found to be a function of the number of phosphate groups on the myo-inositol ring. The cation-myoinositol phosphate complexes are more soluble as the number of phosphate groups decreases. There is also some evidence for weaker complexes when phosphate groups are removed from phytate. In addition, the binding affinity of cations to myo-inositol phosphates has been shown to be affected by the distribution of the phosphate residues on the myo-inositol ring.

The formation of insoluble metal cation-phytate complexes at physiological pH-values is regarded as the major reason for a poor mineral availability, because these complexes are essentially non-absorbable from the gastrointestinal tract. Most studies have shown an inverse relationship between phytate content and mineral availability, although there are great differences in the behaviour of individual minerals. Zn^{2+} was reported to be the essential mineral most adversely affected by phytate [13,14]. Zn^{2+} deficiency in humans was first reported in 1963 in Egyptian boys whose diets consisted mainly of bread and beans [20, 43]. These patients, who were characterised by dwarfism and hypogonadism, showed a response to dietary Zn^{2+} supplementation. It became accepted that the presence of phytate in plant-based foods is an important factor in the reduction of Zn^{2+} absorption.

Phytate affects Zn^{2+} absorption in a dose-dependent manner. There is, however, some lack of agreement among studies, particularly with respect to specific foods and their individual components. In addition, phytate was shown not only to depress the

availability of dietary Zn^{2+} , but also to affect Zn^{2+} homeostasis negatively [15]. A great deal of controversy exists regarding the effect of phytate on the availability of dietary iron [14, 21]. Much of this controversy may be due to the low absorption of iron in general, the presence of different iron-phytates with different solubility, and the existence of two types of food iron, heme and nonheme iron.

Heme iron is better absorbed and its absorption is little affected by dietary factors; nonheme iron, however, is less easily absorbed, and its absorption is affected by other dietary factors. Since many human studies indicate that phytate has a very strong inhibitory effect on iron absorption, it is well accepted today, that phytate appears to be the major but not the only contributor to the reduction in iron availability in man [22, 44]. Human studies also indicated that phytate inhibits Ca^{2+} absorption, but the effect of phytate on Ca^{2+} availability seems to be less pronounced compared to that on the availability of iron and particularly Zn^{2+} [7, 14]. This may be due to the relatively high Ca^{2+} content of plant-based foods, the capability of the bacterial flora in the colon to dephosphorylate phytate and the fact, that Ca^{2+} could be absorbed from the colon [23]. Relatively few studies have dealt with the effects of phytate on dietary Cu^{2+} , Mn^{2+} and Mg^{2+} utilisation. Phytate has been shown to decrease their bioavailability in in vivo studies, but it appears that the effect of phytate on Cu^{2+} , Mn^{2+} and Mg^{2+} availability is less marked than those for some other essential elements [13,14].

The fact that phytate phosphorus is poorly available to single stomached living beings including man was already demonstrated [24, 25]. Phosphorus is absorbed as ortho-phosphate and therefore the utilization of phytate-phosphorus by single-stomached living beings will largely depend on their capability to dephosphorylate phytate. It was already shown, that the human small intestine has only a very limited capability to hydrolyse phytate [26] due to the lack of endogenous phytate-degrading enzymes (phytases) and the limited microbial population in the upper part of the digestive tract.

b) Effect on protein digestibility

Phytate interactions with proteins are pH-dependent [5, 7]. At pH-values below the isoelectric point of the protein, the anionic phosphate groups of phytate bind strongly to the cationic groups of the protein to form insoluble complexes that dissolve only below pH 3.5. The α - NH_2 terminal group, the ϵ - NH_2 of lysine, the imidazole group of histidine and guanidyl group of arginine have been implicated as protein binding sites for phytate at low pH-values. These low pH proteinphytate complexes are disrupted by the competitive action of multivalent cations. Above the isoelectric point of the protein, both protein and phytate have a negative charge, but in the presence of multivalent cations,

however, soluble protein-cation-phytate complexes occur. The major protein binding site for the ternary complex appears to be the nonprotonated imidazole group of histidine, but the ionized carboxyl group of the protein are also suggested sites. These complexes may be disrupted by high ionic strength, high (pH > 10), and high concentrations of the chelating agents.

Phytate is known to form complexes with proteins at both acidic and alkaline pH [5]. This interaction may effect changes in protein structure that can decrease enzymatic activity, protein solubility and proteolytic digestibility. However, the significance of protein-phytate complexes in nutrition is still under scrutiny. Strong evidence exists that phytate-protein interactions negatively affect protein digestibility in vitro and the extent of this effect depends on the protein source [5]. A negative effect of phytate on the nutritive value of protein, however, was not clearly confirmed in studies with simple-stomached animals [7, 45]. While some have suggested phytate does not affect protein digestibility, others have found an improvement in amino acid availability with decreasing levels of phytate. This difference may be at least partly due to the use of different protein sources. Of nutritional significance might be also the inhibition of digestive enzymes such as α -amylase [46,47], lipase [48] or proteinases [49,51], such as pepsin, trypsin and chymotrypsin, by phytate as shown in in vitro studies. The inhibitory effect increases with the number of phosphate residues per myo-inositol molecule and the myo-inositol phosphate concentration. This inhibition may be due to the non-specific nature of phytateprotein.

interactions, the chelation of calcium ions which are essential for the activity of trypsin and α -amylase, or the interaction with the substrates of these enzymes. The inhibition of proteases may be partly responsible for the reduced protein digestibility. Phytate has also been considered to inhibit α -amylase in vivo as indicated by a negative relationship between phytate intake and blood glucose response [50, 52].

III. BENEFICIAL HEALTH EFFECTS OF PHYTATE

In the view of the above results, the evidence seems overwhelming that high intakes of phytate can have adverse effects on mineral uptake in humans. In the last years, however, some novel metabolic effects of phytate or some of its degradation products have been recognised. Dietary phytate was reported to prevent kidney stone formation [8], protect against diabetes mellitus [9], caries [10], atherosclerosis and coronary heart disease [11] as well as against a variety of cancers [12]. The levels of phytate and its dephosphorylation products in urine, plasma and other biological fluids are fluctuating with ingestion or deprivation of phytate in the human diet [53]. Therefore, the reduction in phytate intake in developed compared to developing countries

might be one factor responsible for the increase in diseases typical for Western societies such as diabetes mellitus, renal lithiasis, cancer, atherosclerosis and coronary heart diseases. It was suggested that phytate exerts the beneficial effects in the gastrointestinal tract and other target tissues through its chelating ability, but additional mechanisms have also been discussed. Moreover, the potential beneficial effects of phytate in the prevention of severe poisoning should be considered.

One to two percent calcium phytate in the diet has been found to protect against dietary Pb^{2+} in experimental animals and in human volunteers [54]. Furthermore, calcium phytate was capable of lowering blood Pb^{2+} levels [7, 55]. Thus, phytate seems to be a helpful means to counteract acute oral Pb^{2+} toxicity. The effect of calcium phytate on acute Cd^{2+} toxicity is still discussed controversially, but the majority of studies point to an improved Cd^{2+} absorption in the presence of phytate [56,57]. This may result in a Cd^{2+} accumulation in liver and kidney.

Diabetes mellitus is one of the most common nutrition-dependent diseases in Western society. It may be caused by hyper-caloric diets with high percentage of quickly available carbohydrates. Foods that result in low blood glucose response have been shown to have great nutritional significance in the prevention and management of diabetes mellitus. In this regard phytate-rich foods are of interest, since a negative relationship between phytate intake and blood glucose response was reported [9,52]. For example, phytate-enriched unleavened bread based on white flour reduced the in vitro starch digestibility besides flattening the glycemic response in five healthy volunteers in comparison with bread without phytate addition [52]. The in vitro reduction of starch digestion was positively correlated with the myo-inositol phosphate concentration and negatively with the number of phosphate groups on the myo-inositol ring. It has to be noted, that there are also studies which have not found an inhibition of α -amylase and starch digestion by phytate.

a) *Phytate and Coronary Heart Disease*

Heart disease is a leading cause of death in Western countries, yet it is low in Japan and developing countries. Elevated plasma cholesterol or more specifically, elevated Low Density Lipoprotein cholesterol concentrations have been shown to be one of the risk factors. It has been proposed that dietary fibre or more specifically phytate, as a component of fibre, may influence the aetiology of heart disease [58]. Animal studies have demonstrated that dietary phytate supplementation resulted in significantly lowered serum cholesterol and triglyceride levels [11]. This effect was accompanied by decrease in serum zinc level and in zinc-copper ratio. Thus, the hypothesis was put forward that coronary heart disease is predominantly a disease of imbalance

in regard to zinc and copper metabolism [59]. The hypothesis is also based on the production of hypercholesterolemia, which is a major factor in the aetiology of coronary heart disease, in rats fed a diet with a high ratio of zinc and copper [60]. It was thought that excess zinc in the diets resulted in decreased copper uptake from the small intestine, since both minerals compete for common mucosal carrier systems. As phytate preferentially binds zinc rather than copper [61], it was presumed that phytate exerts its effect probably by decreasing zinc without affecting copper absorption. It should be pointed out that the support for the preventive role of phytate in heart disease is based only on a few animal and in vitro studies. Results from human studies are still lacking.

b) *Phytate and Renal Lithiasis*

The increase of renal stone incidence in northern Europe, North America, and Japan has been reported to be coincident with the industrial development of these countries, making dietary intake suspect. Epidemiological investigations found that there were substantial differences in renal stone incidences between white and black residents of South Africa [62]. The major dietary difference is that, compared to the white population, blacks consumed large amounts of foods containing high levels of fibre and phytate. Furthermore, a high phytate diet has been used effectively to treat hypercalciuria and renal stone formation in humans [7, 63]. In recent years, research on phytate as a potent inhibitor of renal stone formation has been intensified [8, 64,65]. By comparing a group of active calcium oxalate stone formers with healthy people it was demonstrated that urinary phytate was significantly lower for stone formers [8]. Therefore, in vitro and in vivo experiments as well as clinical studies clearly demonstrate that phytate plays an important role in preventing the formation of calcium oxalate and calcium phosphate crystals, which function as nuclei for kidney stone development. Because excretion of low phytate amounts in the urine was shown to be an important risk factor in the development of renal calculi and urinary excretion of phytate decreased significantly after intake of a phytate-free diet [64], the importance of dietary phytate in maintaining adequate urinary levels to permit effective crystallization inhibition of calcium salts and consequently preventing renal stone development was demonstrated.

c) *Phytate and Cancer*

The frequency of colonic cancer varies widely among human populations. It is a major cause of morbidity and mortality in Western society. The incidence of cancer, especially large intestinal cancer has been associated principally with dietary fat intake and is inversely related to the intake of dietary fibre. It was further suggested that the apparent relationship between fibre intake and rate of colonic cancer might arise

from the fact that many fibre-rich foods contain large amounts of phytate and that this latter might be the critical protective element, since an inverse correlation between colon cancer and the intake of phytate-rich fibre foods, but not phytate-poor fibre foods has been shown [66]. A high phytate intake may also be an important factor in reducing the breast and prostate cancer mortality in man [12]. Both in vivo and in vitro experiments have shown striking anticancer effects of phytate. It was demonstrated that phytate is a broad-spectrum antineoplastic agent, affecting different cells and tissue systems [12]. Phytate inhibited the growth of human cell lines such as leukaemic haematopoietic K-562 cell line [67,68], colon cancer HT-29 cell line [69], breast cancer cell lines [70], cervical cancer cell lines [71], prostate cancer cell lines [72,74], HepG2 hepatoma cell line [75], mesenchymal tumour cells [76], murine fibrosarcoma tumour cells [76], and rhabdomyosarcoma cells [77] in a dose- and time-dependent manner. However, cells from different origin have different sensitivity to phytate, suggesting that phytate may affect different cell types through different mechanisms of action. It was also demonstrated, that phytate has the potential to induce differentiation and maturation of malignant cells, which often results in reversion to the normal phenotype [68]. Phytate was further shown to increase differentiation of human colon carcinoma HT-29 cells [69,78], prostate cancer cells [72, 73], breast cancer cells [70], and rhabdomyosarcoma cells [77]. The effectiveness of phytate as a cancer preventive agent was also shown in colon cancer induced in rats and mice. Phytate was effective in a dose-dependent manner given either before or after carcinogen administration.

The phytate-treated animals demonstrated a significantly lower tumour number and size. Studies using other experimental models showed that the antineoplastic properties of phytate were not restricted to the colon. Phytate significantly reduced experimental mammary carcinoma [79,80, 83], skin papillomas [84], tumour size of metastatic fibrosarcoma and experimental lung metastases [76], growth of rhabdomyosarcoma cells [77], and regression of pre-existing liver cancers [75,85]. In addition synergistic cancer inhibition by phytate when combined with inositol was demonstrated in several cancers in experimental animals [76,81,82,86]. The in vivo experiments were performed either by adding phytate to the diet or by giving phytate via drinking water. Comparable or even stronger tumour inhibition was obtained with much lower concentrations of phytate when it was given in drinking water.

d) Mechanism of action

The mechanisms involved in the anticancer activity of phytate are not fully understood. It was suggested that phytate exerts the beneficial effects through its chelating ability, but additional mechanisms have also been discussed. Because several myo-inositol

phosphates, including phytate, are present as intracellular molecules and because the second messenger D-myo-inositol (1,4,5) trisphosphate is bringing about a range of cellular functions including cell proliferation via mobilising intracellular Ca^{2+} [87], phytate was proposed to exert its anticancer effect by affecting cell signalling mechanisms in mammalian cells [68]. About 35 of the 63 possible myo-inositol phosphate isomers were identified in different types of cells [87]. Depending on cell type, that is different receptors, phosphatases, and kinases, myo-inositol phosphates were linked with different physiological effects, such as basic cell functions like secretion and contraction as well as functions like cell division, cell differentiation and cell death. Therefore, practically every myo-inositol phosphate isomer extracellularly present and may have a metabolic effect by activating receptors, by being metabolised by phosphatases and kinases or by acting as inhibitors of these intracellular proteins after being internalised by cells. An effect of extracellular phytate on the concentration of several intracellular myo-inositol phosphate esters has already been demonstrated in human erythroleukemia cells [68]. Furthermore, it has been recently reported that highly negatively charged myo-inositol polyphosphates can cross the plasma membrane and be internalised by cells. Myo-inositol hexakisphosphate was shown to enter HeLa cells followed by an intracellular dephosphorylation to partially phosphorylated myo-inositol phosphates [71], whereas myo-inositol (1,3,4,5,6) pentakisphosphate showed a quite slow turnover after internalisation by SKOV-3 cells [88]. It was suggested that the anticancer activity of phytate is actually due to its dephosphorylation to lower forms. Myo-inositol (1,3,4,5, 6) pentakisphosphate inhibits specifically phosphatidylinositol 3-kinase, the enzyme catalysing the phosphorylation of inositol phospholipids at the D3 position to generate 3'-phosphorylated phosphoinositides [89], which act by recruiting specific signalling proteins to the plasma membrane [90]. Activation of phosphatidylinositol 3-kinase is a crucial step in some events leading to angiogenesis, the formation of a mature vasculature from a primitive vascular network [90, 91]. Angiogenesis is involved in pathologies such as arteriosclerosis and tumour growth.

The observed anticancer effects of phytate could be mediated through several other mechanisms. Besides affecting tumour cells, phytate can act on a host by restoring its immune system. Phytate augments natural killer cell activity in vitro and normalises the carcinogen-induced depression of natural killer cell activity in vivo [7, 92]. The anti-oxidant role of phytate is known and widely accepted. The 1,2,3-trisphosphate grouping in phytate has a conformation that uniquely provides a specific interaction with iron to completely inhibit its capability to catalyse hydroxyl radical formation from the Fenton reaction [93]. Chelation of iron to the 1, 2, 3-trisphosphate grouping may also reduce the

likelihood for iron-catalysed lipid peroxidation [94]. It is as yet uncertain whether physiological intakes of phytate can significantly improve the anti-oxidant status in man. The anticancer action of phytate may be further related to mineral binding ability or other positively charged compounds. By complexing Zn^{2+} and /or Mg^{2+} , phytate can affect activity of enzymes essential for DNA synthesis. Due to inhibition of starch digestion in the small intestine, undigested and unabsorbed starch will reach the colon where it may either contribute to faecal bulk and increase the dilution of potential carcinogens, or it may be fermented to short-chain fatty acids, which may subsequently decrease the colonic pH. The increased production of short-chain fatty acid, particularly butyrate, may play a protective role in colon carcinogenesis, because butyrate has been shown in several in vitro studies to slow down the growth rate of human colorectal cancer cell lines [95,96]. Decreased pH has been suggested to be protective of colon carcinogenesis [97] by possibly causing alterations in the metabolic activity of colonic flora, altering bile acid metabolism and inhibiting ammonia production and absorption [98, 99].

IV. CONCLUSION

Phytate is a principal chelating agent in cereal-based foods and is capable of impairing divalent mineral bioavailability through binding. Phytate has been recognized as an antinutrient due to its adverse effects. It reduced the bioavailability of minerals and caused growth inhibition. Many studies reported that phytate in plant foods binds essential dietary minerals in the digestive tract, making them unavailable for absorption. It forms insoluble complexes with Cu^{2+} , Zn^{2+} , Fe^{3+} and Ca^{2+} and as a result reduces the bioavailability of these essential minerals. Many animal feedings of plant food trials reveal that lower bioavailability of zinc, calcium, magnesium, phosphorus and iron are due to the presence of phytate. This is the main reason why phytate has been considered as an antinutrient.

Recent studies on phytate have shown its beneficial effects such as decrease in blood lipids, decrease in blood glucose response and cancer risk. In addition, a high phytate diet is used in the inhibition of dental caries and platelet aggregation, for the treatment of hypercalciuria and kidney stones in humans, and as antidote activity against acute lead poisoning. The beneficial health effects of phytate are more significant for populations in developed countries because of the higher incidence of cancer especially colon cancer which is associated with higher fat and lower fibre rich food intakes. Such populations generally do not suffer from mineral deficiencies. On the one hand, the chelating ability of phytate is considered to be a detriment to one's health whilst, on the other hand, many researchers consider this ability to bind with minerals as its most powerful asset. Such a variant topic

signifies that more intensive studies are needed to obtain better insight into the mechanism responsible for the "friend or foe" challenge of phytate. Moreover, regardless of a series of researches on the positive and negative features of phytate, the information on the dosage for humans eliciting positive or negative effects is limited and the optimal dosage for clinical therapies is yet to be determined.

V. ACKNOWLEDGEMENT

I acknowledge all the Authors I used as a references in preparing this review paper. The author have no conflict of interests.

REFERENCES RÉFÉRENCES REFERENCIAS

1. Loewus FA. Biosynthesis of phytate in food grains and seeds. In: Reddy NR, Sathe SK (Eds.). Food Phytates. CRC Press, Boca Raton Florida, 2002; 53–61.
2. Graf E, Eaton JW. Antioxidant functions of phytic acid. *Free Rad Biol Med* 1990; 8: 61–69.
3. Reddy NR, Sathe SK, Salunkhe DK. Phytates in legumes and cereals. *Adv Food Res* 1982; 28: 1–92.
4. Cosgrove, D. J. Inositol Phosphates Their Chemistry, Biochemistry and Physiology. *In Studies in Inorganic Chemistry*. Elsevier Scientific Publishing Company., The Netherlands. 1980; 4: 122-129.
5. Cheryan M. Phytic acid interactions in food systems. *Crit Rev Food Sci Nutr* 1980; 13: 297–335.
6. Weaver, C.M., and Kannan, S. Phytate and mineral bioavailability. In: Reddy, N.R., Sathe, S.K. (Eds.), Food phytates. CRC Press, Boca Raton, FL, 2002; pp. 211–223.
7. Greiner R, Konietzny U, Jany K-D. Phytate - an undesirable constituent of plant-based foods? *Jour - nal für Ernährungsmedizin* 2006; 8 (3), 18-28.
8. Grases F, March JG, Prieto RM, Simonet BM, Costa-Bauzá A, García-Raja A, Conte A. Urinary phytate in calcium oxalate stones formers and healthy people. *Scand J Urol Nephrol* 2000; 34: 162–164.
9. Thompson LU. Potential health benefits and problems associated with antinutrients in foods. *Food Res Int* 1993; 26: 131–149.
10. Kaufman HW, Kleinberg I. Effect of pH on calcium binding by phytic acid and its inositol phosphoric acid derivatives and on the solubility of their calcium salts. *Archs Oral Biol* 1971; 16: 445–460.
11. Jariwalla RJ, Sabin R, Lawson S, Herman ZS. Lowering of serum cholesterol and triglycerides and modulation of divalent cations by dietary phytate. *J Appl Nutr* 1990; 42: 18–28.
12. Vucenik I, Shamsuddin AM. Cancer inhibition by inositol hexaphosphate (IP6) and inositol: From laboratory to clinic. *J Nutr* 2003; 133: 3778S–3784S.

13. Lönnerdal B. Phytic acid-trace element (Zn, Cu, Mn) interactions. *Int J Food Sci Technol* 2002; 37: 749–758.
14. Lopez HW, Leenhardt F, Coudray C, Remesy C. Minerals and phytic acid interactions: is it a real problem for human nutrition? *Int J Food Sci Technol* 2002; 37: 727–739.
15. Oberleas D. The role of phytate in zinc bioavailability and homeostasis. In: Inglett GE (Ed.), *Nutritional bioavailability of zinc*. American Chemical Society, Washington DC, 1983; 145–158.
16. Torre M, Rodriguez AR, Saura-Calixto F. Effects of dietary fiber and phytic acid on mineral bioavailability. *Crit Rev Food Sci Nutr* 1991; 1: 1–22.
17. Askar A, El-Samahy SK, Abd El-Fadeel MG. Phytinsäure in Lebensmittel. *Alimenta* 1983; 22: 131–137.
18. Wise A. Dietary factors determining the biological activities of phytate. *Nutr Abstr Rev Clin Nutr* 1983; 53: 791–806.
19. Fox MRS, Tao SH. Antinutritive effects of phytate and other phosphorylated derivatives. In: Hathcock JN (Ed.). *Nutritional Toxicology Vol III*. Academic Press, New York, 1989; 59–96.
20. Prasad AS, Miale Jr A, Farid Z, Sandstead HH, Schuler AR. Zinc metabolism in patients with the syndrome of iron deficiency anaemia, hepatosplenomegaly, dwarfism, and hypogonadism. *J Lab Clin Med* 1963; 61: 537–549.
21. Hallberg L, Rossander L, Skanberg AB. Phytates and the inhibitory effect of bran on iron absorption in man. *Am J Clin Nutr* 1987; 45: 988–996.
22. Brune M, Rossander-Hulthén L, Hallberg L, Glerup A, Sandberg AS. Iron absorption from bread in humans: Inhibiting effects of cereal fiber, phytate and inositol phosphates with different numbers of phosphate groups. *J Nutr* 1992; 122: 442–449.
23. Sandström B, Cederblad A, Stenquist B, Andersson H. Effect of inositol hexaphosphate on retention of zinc and calcium from the human colon. *Eur J Clin Nutr* 1990; 44: 705–708.
24. Lantzsich HJ, Hillenbrand S, Scheuermann SE, Menke KH. Comparative study of phosphorus utilization from wheat, barley and corn diets by young rats and pigs. *J Anim Physiol Anim Nutr* 1992; 67: 123–132.
25. Walz OP, Pallauf J. Microbial phytase combined with amino acid supplementation reduces P and N excretion of growing and finishing pigs without loss of performance. *Int J Food Sci Technol* 2002; 37: 845–848.
26. Iqbal TH, Lewis KO, Cooper BT. Phytase activity in the human and rat small intestine. *Gut* 1994; 35: 1233–1236.
27. IUFoST, (2008). CHEMICAL HAZARDS IN FOOD. *IUFoST Scientific Information Bulletin*.
28. Greiner, R., and Konietzny, U., (2006). Phytase for Food Application. *Food Technology. Biotechnology* 44, 125-140.
29. Oladimeji, M. O., Akindahunsi, A. A., & Okafor, A. F., (2000). Investigation of the bioavailability of zinc and calcium from some tropical tubers. *Nahrung*, 44, 136–137 (Nr2, S).
30. Davis, N. T., and Warrington, S., (1986). The phytic acid, mineral, trace element, protein and moisture content of UK Asian immigrant foods. *Human Nutrition and Applied Nutrition*, 40A, 49–59.
31. Jenab, M., and Thompson, L.U., (2002). Role of phytic acid in cancer and other diseases. In: Reddy, N.R., Sathe, S.K. (Eds.), *Food Phytates*. CRC Press, Boca Raton, FL, pp. 225–248. *Journal of Clinical Nutrition* 8, 64-74.
32. Shamsuddin, A. M., (2002). Anti-cancer function of phytic acid. *International Journal of Food Science and Technology*, 37(7), 769–782.
33. Barker, C. J., and Berggren, P., (1999). Inositol hexakisphosphate and beta-cell stimulus secretion coupling. *Anticancer Research*, 19, 3737–3742.
34. Selvam, R., (2002). Calcium oxalate stone disease: Role of lipid peroxidation and antioxidants. *Urological Research*, 30(1), 35–47.
35. Golden, M., (2009). Nutrient requirements of moderately malnourished populations of children. *Food Nutr Bull*.
36. Bhandari, M. R., and Kawabata, J., (2004). Cooking effects on oxalate, phytate, trypsin, cyanide and amylase inhibitors of wild yam tubers of Nepal. *Journal of Food Composition and Analysis*, 19: 524–530.
37. Sandberg AS. The effect of food processing on phytate hydrolysis and availability of iron and zinc. In: Friedman M (Ed.). *Nutritional and Toxicological Consequences of Food Processing*, Plenum Press, New York, 1991; 499–508.
38. Simpson CJ, Wise A. Binding of zinc and calcium to inositol phosphates (phytate) in vitro. *Br J Nutr* 1990; 64: 225–232.
39. Davidsson L, Galan P, Kastenmeyer P, Cherouvrier F, Juillerat MA, Hercberg S, Hurrell RF. Iron bioavailability studied in infants: The influence of phytic acid and ascorbic acid in infant formulas based on soy isolate. *Pediatr Res* 1994; 36: 816–822.
40. Gillooly M, Bothwell TH, Torrance JD, MacPhail AP, Derman DP, Bezwoda WR, Mills W, Charlton RW, Mayet F. The effects of organic acids, phytates and polyphenols on the absorption of iron from vegetables. *Br J Nutr* 1983; 49: 331–342.
41. Siegenberg D, Baynes RD, Bothwell TH, Macfarlane BJ, Lamparelli RD, Car NG, MacPhail P, Schmidt U, Tal A, Mayet F. Ascorbic acid prevents the dose-dependent inhibitory effects of polyphenols and

- phytates on nonheme-iron absorption. *Am J Clin Nutr* 1991; 53: 537–541.
42. Sandberg AS, Rossander-Hulthén L, Türk M. Dietary *Aspergillus niger* phytase increases iron absorption in humans. *J Nutr* 1996; 126: 476–480.
 43. Sandberg AS, Larsen T, Sandström B. High dietary calcium level decreases colonic phytate degradation in pigs fed a rapeseed diet. *J Nutr* 1993; 123: 559–566.
 44. Wise A, Gilbert DJ. Caecal microbial phytate hydrolysis in the rat. *Human Nutr Food Sci Nutr* 1987; 41F: 47–54.
 45. Brune M, Rossander L, Hallberg L. Iron absorption: no intestinal adaptation to a high-phytate diet. *Am J Clin Nutr* 1989; 49: 542–545.
 46. Deshpande SS, Cheryan M. Effects of phytic acid, divalent cations, and their interactions on alpha-amylase activity. *J Food Sci* 1984; 49: 516–519, 524.
 47. Knuckles BE, Betschart AA. Effect of phytate and other myoinositol phosphate esters on alpha-amylase digestion of starch. *J Food Sci* 1987; 52: 719–721.
 48. Knuckles BE. Effect of phytate and other myoinositol phosphate esters on lipase activity. *J Food Sci* 1988; 53: 250–252.
 49. Deshpande SS, Damodaran S. Effect of phytate on solubility, activity and conformation of trypsin and chymotrypsin. *J Food Sci* 1989; 54: 695–699.
 50. Inagawa J, Kiyosawa I, Nagasawa T. Effect of phytic acid on the digestion of casein and soyabean protein with trypsin, pancreatin and pepsin. *Nippon Eiyo Shokuryo Gakkaishi* 1987; 40: 367–373.
 51. Singh M, Krikorian AD. Inhibition of trypsin activity in vitro by phytate. *J Agric Food Chem* 1982; 30: 799–800.
 52. Yoon JH, Thompson LU, Jenkins DJA. The effect of phytic acid on in vitro rate of starch digestibility and blood glucose response. *Am J Clin Nutr* 1983; 38: 835–842.
 53. Grases F, Simonet BM, Prieto RM, March JG. Variation of InsP4, InsP5 and InsP6 levels in tissues and biological fluids depending on dietary phytate. *J Nutr Biochem* 2001; 12: 595–601.
 54. Wise A. Protective action of calcium phytate against acute lead toxicity in mice. *Bull Environm Contam Toxicol* 1981; 27: 630–633.
 55. Wise A. Blood lead levels after chronic feeding to mice of lead acetate with calcium phytate in the diet. *Bull Environm Contam Toxicol* 1982; 29: 550–553.
 56. Jackl GA, Rambeck WA, Koumer WE. Retention of cadmium in organs of the rat after a single dose of labelled cadmium-3-phytate. *Biol Trace Elem Res* 1985; 7: 69–74.
 57. Rimbach G, Pallauf J, Walz OP. Effect of microbial phytase on cadmium accumulation in pigs. *Arch Anim Nutr* 1996; 49: 279–286.
 58. Potter SM. Overview of proposed mechanisms for the hypocholesterolemic effect of soy. *J Nutr* 1995; 125: 606S–611S.
 59. Klevay LM. Coronary heart disease: the Zinc/Copper hypothesis. *Am J Clin Nutr* 1975; 28: 764–774.
 60. Klevay LM. Hypercholesterolemia in rats produced by an increase in the ratio of zinc to copper ingestion. *Am J Clin Nutr* 1973; 26: 1060–1068.
 61. Persson H, Türk M, Nyman M, Sandberg AS. Binding of Cu²⁺, Zn²⁺, and Cd²⁺ to inositol tri-, tetra-, penta-, and hexaphosphates. *J Agric Food Chem* 1998; 46: 3194–3200.
 62. Zhou JR, Eрман Jr JW. Phytic acid in health and disease. *Crit Rev Food Sci Nutr* 1995; 35: 495–508.
 63. Ohkawa T, Ebiduno S, Kitagawa M, Morimoto S, Miyazaki Y, Yasukawa S. Rice bran treatment for patients with hypercalciuric stones: Experimental and clinical studies. *J Urol* 1984; 132: 1140–1145.
 64. Grases F, Costa-Bauzá A. Phytate (IP6) is a powerful agent preventing calcifications in biological fluids: usefulness in renal lithiasis treatment. *Anticancer Res* 1999; 19: 3717–3722.
 65. Grases F, Perello J, Prieto RM, Simonet BM, Torres JJ. Dietary myo-inositol hexaphosphate prevents dystrophic calcifications in soft tissues: a pilot study in Wistar rats. *Life Sci* 2004; 75: 11–19.
 66. Graf E, Eaton JW. Dietary suppression of colonic cancer. Fiber or phytate? *Cancer* 1985; 56: 717–718.
 67. Lambertenghi Delliers G, Servida F, Fracchiola NS, Ricci C, Borsotti C, Colombo G, Soligo D. Effect of inositol hexaphosphate (IP6) on human normal and leukaemic haematopoietic cells. *Br J Haematol* 2002; 117: 577–587.
 68. Shamsuddin AM, Baten A, Lalwani ND. Effects of inositol hexaphosphate on growth and differentiation in K-562 erythroleukemia cell line. *Cancer Lett* 1992; 64: 195–202.
 69. Sakamoto K, Venkatraman G, Shamsuddin AM. Growth inhibition and differentiation of HT-29 cells in vitro by inositol hexaphosphate (phytic acid). *Carcinogenesis* 1993; 14: 1815–1819.
 70. Shamsuddin AM, Yang GY, Vucenic I. Novel anticancer functions of IP6: Growth inhibition and differentiation of human mammary cancer cell lines in vitro. *Anticancer Res* 1996; 16: 3287–3292.
 71. Ferry S, Matsuda M, Yoshida H, Hirata M. Inositol hexakisphosphate blocks tumor cell growth by activating apoptotic machinery as well as by inhibiting the Akt/NFkB-mediated cell survival pathway. *Carcinogenesis* 2002; 23: 2031–2041.
 72. Shamsuddin AM, Yang GY. Inositol hexaphosphate inhibits growth and induces differentiation of PC-3 human prostate cancer cells. *Carcinogenesis* 1995; 16: 1975–1979.
 73. Singh RP, Agarwal C, Agarwal R. Inositol hexakisphosphate inhibits growth, and induces G1 arrest

- and apoptotic death of prostate carcinoma DU145 cells: modulation of CDK1-CDKcyclin and pRb-related protein-E2F complexes. *Carcinogenesis* 2003; 24: 555–563.
74. Zi X, Singh RP, Agarwal R. Impairment of erbB1 receptor and fluid-phase endocytosis and associated mitogenic signaling by inositol hexaphosphate in human prostate carcinoma DU145 cells. *Carcinogenesis* 2000; 21: 2225–2235.
 75. Vucenik I, Tantivejkul K, Zhang ZS, Cole KE, Saied I, Shamsuddin AM. IP6 in treatment of liver cancer. I. IP6 inhibits growth and reverses transformed phenotype in HepG2 human liver cancer cell line. *Anticancer Res* 1998; 18: 4083–4090.
 76. Vucenik I, Tomazic VJ, Fabian D, Shamsuddin AM. Antitumor activity of phytic acid (inositol hexaphosphate) in murine transplanted and metastatic fibrosarcoma, a pilot study. *Cancer Lett* 1992; 65: 9–13.
 77. Vucenik I, Kalebic T, Tantivejkul K, Shamsuddin AM. Novel anticancer function of inositol hexaphosphate: inhibition of human rhabdomyosarcoma in vitro and in vivo. *Anticancer Res* 1998; 18: 1377–1384.
 78. Yang GY, Shamsuddin AM. IP6-induced growth inhibition and differentiation of HT-29 human colon cancer cells: Involvement of intracellular inositol phosphates. *Anticancer Res* 1995; 15: 2479–2488.
 79. Hirose M, Hoshiya T, Akagi K, Futakuchi M, Ito N. Inhibition of mammary gland carcinogenesis by green tea catechins and other naturally occurring antioxidants in female Spargue-Dawley rats pretreated with 7,12-dimethylbenz(a)anthracene. *Cancer Lett* 1994; 83: 149–156.
 80. Shivapurkar N, Tang Z, Frost A, Alabaster O. A rapid dual organ rat carcinogenesis bioassay for evaluating the chemoprevention of breast and colon cancer. *Cancer Lett* 1996; 100: 169–179.
 81. Vucenik I, Sakamoto K, Bansal M, Shamsuddin AM. Inhibition of rat mammary carcinogenesis by inositol hexaphosphate (phytic acid). A pilot study. *Cancer Lett* 1993; 75: 95–102.
 82. Vucenik I, Yang GY, Shamsuddin AM. Inositol hexaphosphate and inositol inhibit DMBA-induced rat mammary cancer. *Carcinogenesis* 1995; 16: 1055–1058.
 83. Vucenik I, Yang GY, Shamsuddin AM. Comparison of pure inositol hexaphosphate and high-bran diet in the prevention of DMBA-induced rat mammary carcinogenesis. *Nutr Cancer* 1997; 28: 7–13.
 84. Ishikawa T, Nakatsuru Y, Zarkovic M, Shamsuddin AM. Inhibition of skin cancer by IP6 in vivo: Initiation-promotion model. *Anticancer Res* 1999; 19: 3749–3752.
 85. Vucenik I, Zhang ZS, Shamsuddin AM. IP6 in treatment of liver cancer. II. Intra-tumoral injection of IP6 regresses pre-existing human liver cancer xenotransplanted in nude mice. *Anticancer Res* 1998; 18: 4091–4096.
 86. Shamsuddin AM, Ullah A, Chakravarthy AK. Inositol and inositol hexaphosphate suppress cell proliferation and tumor formation in CD-1 mice. *Carcinogenesis* 1989; 10: 1461–1463.
 87. Shears SB. The versatility of inositol phosphates as cellular signals. *Biochim Biophys Acta* 1998; 1436: 49–67.
 88. Maffucci T, Piccolo E, Cumashi A, Iezzi M, Riley AM, Saiardi A, Godage HY, Rossi C, Brogginini M, Iacobelli S, Potter BVL, Innocenti P, Falasca M. Inhibition of the phosphatidylinositol 3-Kinase/Akt pathway by inositol pentakisphosphate results in antiangiogenic and antitumor effects. *Cancer Res* 2005; 65: 8339–8349.
 89. Foster FM, Traer CJ, Abraham SM, Fry MJ. The phosphoinositide (PI) 3-kinase family. *J Cell Sci* 2003; 116: 3037–3040.
 90. Maffucci T, Falasca M. Specificity in pleckstrin homology (PH) domain membrane targeting: a role for a phosphoinositide protein co-operative mechanism. *FEBS Lett* 2001; 506: 173–179.
 91. Carmeliet P. Angiogenesis in health and disease. *Nat Med* 2003; 9: 653–660.
 92. Baten A, Ullah A, Tomazic VJ, Shamsuddin AM. Inositol-phosphate-induced enhancement of natural killer cell activity correlates with tumor suppression. *Carcinogenesis* 1989; 10: 1595–1598.
 93. Hawkins PT, Poyner DR, Jackson TR, Letcher AJ, Lander DA, Irvine RF. Inhibition of iron-catalyzed hydroxyl radical formation by inositol polyphosphate: a possible physiological function for myo-inositol hexakisphosphate. *Biochem J* 1993; 294: 929–934.
 94. Phillippy BQ, Graf E. Antioxidant functions of inositol 1,2,3-trisphosphate and inositol 1,2,3,6-tetrakisphosphate. *Free Rad Biol Med* 1997; 22: 939–946.
 95. Basson MD, Turowski GA, Rashid Z, Hong F, Madri JA. Regulation of human colonic cell line proliferation and phenotype by sodium butyrate. *Dig Dis Sci* 1996; 41: 1989–1993.
 96. Coradini D, Pellizzaro C, Marimpietri D, Abolafio G, Daidone MG. Sodium butyrate modulates cell cycle-related proteins in HT29 human colonic adenocarcinoma cells. *Cell Prolif* 2000; 33: 139–146.
 97. Newmark HL, Lupton JR. Determinants and consequences of colonic luminal pH: implications for colon cancer. *Nutr Cancer* 1990; 14: 161–173.
 98. Mallett AK, Bearne CA, Rowland IR. The influence of incubation pH on the activity of rat and human gut flora enzymes. *J Appl Bacteriol* 1989; 66: 433–437.
 99. Thornton JR. High colonic pH promotes colorectal cancer. *Lancet* 1981; 1: 1081–1083.